Drug Profile
PRO 118
Alternative Names: PRO-118Latest Information Update: 02 Mar 2021
Price :
$50
*
At a glance
- Originator Laboratorios Sophia
- Class Antihistamines; Eye disorder therapies
- Mechanism of Action Histamine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic conjunctivitis
Most Recent Events
- 02 Mar 2021 No development reported - Phase-II for Allergic conjunctivitis (In adolescents, In children, In the elderly, In adults) in Mexico (Ophthalmic)
- 02 Mar 2021 No development reported - Phase-III for Allergic conjunctivitis (In adolescents, In children, In adults) in Mexico (Ophthalmic)
- 01 Oct 2018 Laboratorios Sophia withdraws a phase II trial in Allergic conjunctivitis (In children, In adolescents, In adults, In the elderly) prior to enrolment due to product reformulation in Mexico (Ophthalmic) (NCT01541904)